Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
biotech
life sciences
migraine
8
×
national blog main
clinical trials
new york blog main
eli lilly
fda
indiana blog main
indiana top stories
national
national top stories
new york top stories
raleigh-durham blog main
raleigh-durham top stories
san francisco blog main
san francisco top stories
boston blog main
boston top stories
boulder/denver blog main
boulder/denver top stories
detroit blog main
detroit top stories
san diego blog main
san diego top stories
seattle blog main
seattle top stories
texas blog main
texas top stories
wisconsin blog main
wisconsin top stories
teva pharmaceutical
amgen
cancer
cancer immunotherapy
gene therapy
lasmiditan
merck
novartis
abbvie
What
new
bio
companies
drug
migraine
roundup
approval
class
fda
ipo
approved
drugs
firm
life
medicines
science
week
won
activity
adults
allergan
america
announced
arena’s
arguments
bails
big
biogen
biogen’s
biopharmaceutical
biotech
bounty
brand
bridgebio
capital
car
cig
comeback
commercialized
competitors
Language
unset
Current search:
migraine
×
@xconomy.com
4 years ago
Allergan Wins FDA Nod for First Migraine Pill in New Class of Medicines
@xconomy.com
4 years ago
Bio Roundup: Ichnos Emerges, Beyond CAR-T, BridgeBio Bails & More
@xconomy.com
4 years ago
Pfizer Spinout SpringWorks, Migraine Drug Firm Satsuma Prep IPOs
@xconomy.com
5 years ago
Bio Roundup: Head and Spine Previews, Biogen Moves, IPO Dreams & More
@xconomy.com
5 years ago
At Big Neuro Meeting, Migraine Drug Competitors to Make Oral Arguments
@xconomy.com
5 years ago
Bio Roundup: Biogen’s Strategy, Drug Price Convo, NASH News & More
@xconomy.com
5 years ago
Bio Roundup: Moderna’s IPO, Arena’s Comeback, E-Cig Survey & More
@xconomy.com
5 years ago
Eli Lilly Migraine Drug Approved, the Third in New Class of Medicines